Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Pleural and Pericardial Effusions Associated with Semaglutide: A Case Report.

Stark M, Valentini N

Clinical practice and cases in emergency medicine1 Feb 2026

PMID41666880 (opens in a new tab)PMCIDPMC12890333 (opens in a new tab)DOI10.5811/cpcem.48864 (opens in a new tab)PepBankPUB-41666880
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

IntroductionSemaglutide, a glucagon-like peptide-1 receptor agonist, has gained increasing popularity for managing both type 2 diabetes mellitus and obesity. However, as its use increases, new adverse events are emerging. This case report presents a 70-year-old patient who developed pleural and pericardial effusions likely related to semaglutide use.Case reportFour weeks after being prescribed semaglutide, a 70-year-old woman presented to the emergency department (ED) with shortness of breath. Diagnostic testing in the ED and hospital revealed that she had both pericardial and exudative pleural effusions, along with a positive anti-nuclear antibody and elevated inflammatory markers. Her signs and symptoms improved with steroid administration, and no other etiology was identified.ConclusionThe patient was diagnosed with drug-induced lupus, likely triggered by semaglutide. This case underscores the importance of recognizing and investigating uncommon drug-related complications. With the growing use of semaglutide, clinicians must remain vigilant for rare adverse effects such as pleural effusions to ensure prompt diagnosis and treatment.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    A 70-year-old woman developed pericardial and exudative pleural effusions, with a positive anti-nuclear antibody and elevated inflammatory markers, four weeks after starting semaglutide.

    In plain wordsOne 70-year-old woman developed fluid around the heart and lungs four weeks after starting semaglutide; the authors judged semaglutide the likely cause.

    Peptide
    Semaglutide
    Outcome
    IncreasePleural and pericardial effusions
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Diagnostic testing in the ED and hospital revealed that she had both pericardial and exudative pleural effusions, along with a positive anti-nuclear antibody and elevated inflammatory markers.
    1 context sentence
    Summary · context
    Four weeks after being prescribed semaglutide, a 70-year-old woman presented to the emergency department (ED) with shortness of breath.
  2. 02HumanCase report or seriesSafety outcome

    A 70-year-old woman was diagnosed with drug-induced lupus, likely triggered by semaglutide.

    In plain wordsOne woman was diagnosed with drug-induced lupus that the authors think semaglutide likely triggered.

    Peptide
    Semaglutide
    Outcome
    IncreaseDrug-induced lupus
    Study

    n = 1

    Outcome group
    Adverse events · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The patient was diagnosed with drug-induced lupus, likely triggered by semaglutide.
    1 context sentence
    Summary · context
    Four weeks after being prescribed semaglutide, a 70-year-old woman presented to the emergency department (ED) with shortness of breath.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.